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The effectiveness of a chemotherapy regimen including cisplatin, epirubicin, and estramustine phosphate was evaluated in a series of young patients with prostate cancer. 28 patients with a histological diagnosis of prostatic carcinoma, age < 70 years, performance status (PS) < 2, hormone-refractory status, life expectancy > 3 months, were treated with cisplatin 60 mg/m2 i.v. and epirubicin 60 mg/m2 i.v. every 3 weeks for six cycles. Estramustine phosphate was administered at a dosage of 10 mg/kg p.o. in two divided daily doses during intravenous chemotherapy and until progression thereafter. The response was assessed after three cycles of chemotherapy, evaluating again the disease parameters. In case of partial remission or stable disease, treatment was continued for three additional cycles. The median age was 61.5 years, the median PS was 70. 11 partial remissions, 13 patients with stable disease, and 4 progressions were noted. The response rate (only partial remissions) was 39% (95% confidence limits 21-57%). The median duration of the partial remissions) was 11 (range 6-25) months. A subjective improvement of symptoms was observed in 17 of 19 patients. Toxicity was acceptable with no deaths. The median overall survival was 15 months. The combination studied had activity in young prostate cancer patients, and our results suggest that this subset of patients needs specifically devised chemotherapy regimens.